June 5, 2007 (Toronto) — Exenatide can be an alternative to insulin glargine as an add-on treatment in patients with type 2 diabetes who are already receiving single-agent oral therapy, research ...

LYON, FRANCE--(Marketwired - Dec 22, 2015) - Flamel Technologies (NASDAQ: FLML) today announced positive interim results from a Phase 1a clinical trial in healthy volunteers of a once weekly ...